<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Exploring Jolkinol D Derivatives To Overcome Multidrug Resistance in Cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-04-19">April 19, 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Mariana</forename><forename type="middle">A</forename><surname>Reis</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Pharmacy</orgName>
								<orgName type="laboratory">Research Institute for Medicines (iMed.ULisboa)</orgName>
								<orgName type="institution">Universidade de Lisboa</orgName>
								<address>
									<addrLine>Avenue Prof. Gama Pinto</addrLine>
									<postCode>1649-003</postCode>
									<settlement>Lisbon</settlement>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Omar</forename><forename type="middle">B</forename><surname>Ahmed</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Charite</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gabriella</forename><surname>Spengler</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Medical Microbiology and Immunobiology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">University of Szeged</orgName>
								<address>
									<addrLine>Doḿ teŕ 10</addrLine>
									<postCode>H-6720</postCode>
									<settlement>Szeged</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joseph</forename><surname>Molnaŕ</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Medical Microbiology and Immunobiology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">University of Szeged</orgName>
								<address>
									<addrLine>Doḿ teŕ 10</addrLine>
									<postCode>H-6720</postCode>
									<settlement>Szeged</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hermann</forename><surname>Lage</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Charite</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Maria-Joséu</forename><surname>Ferreira</surname></persName>
							<email>mjuferreira@ff.ulisboa.pt.orcid</email>
							<affiliation key="aff0">
								<orgName type="department">Faculty of Pharmacy</orgName>
								<orgName type="laboratory">Research Institute for Medicines (iMed.ULisboa)</orgName>
								<orgName type="institution">Universidade de Lisboa</orgName>
								<address>
									<addrLine>Avenue Prof. Gama Pinto</addrLine>
									<postCode>1649-003</postCode>
									<settlement>Lisbon</settlement>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">S Supporting Information</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="laboratory">∥ (M.A.R.) Interdisciplinary Centre of Marine and Environ-mental Research (CIIMAR/CIMAR)</orgName>
								<orgName type="institution">University of Porto</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution" key="instit1">Terminal de Cruzeiros do Porto de Leixoẽs</orgName>
								<orgName type="institution" key="instit2">Avenida General Norton de Matos</orgName>
								<address>
									<postCode>4450-208</postCode>
									<settlement>Matosinhos</settlement>
									<region>S/N</region>
									<country>Portugal. ⊥ (H.L.</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="institution">Vivantes Clinics</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country>Germany. Notes</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Journal of Natural Products</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Exploring Jolkinol D Derivatives To Overcome Multidrug Resistance in Cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-04-19">April 19, 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">0BF65FF0DAA206315F6FBC9C62507B0F</idno>
					<idno type="DOI">10.1021/acs.jnatprod.6b01084</idno>
					<note type="submission">Received: November 21, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:47+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Macrocyclic monoacyl lathyrane derivatives bearing a benzoyl moiety were previously found to be strong ABCB1 modulators.</s><s>To explore the effects of different substituents of the aromatic moiety, 14 new compounds (1.1−1.7,</s><s>1.10, and 2.1− 2.4) were prepared from jolkinol D (1), obtained from Euphorbia piscatoria, and from jolkinodiol (2), its hydrolysis derivative.</s><s>Compounds 1.8 and 1.9, having aliphatic moieties, were also obtained.</s><s>The reversal of ABCB1-mediated MDR was evaluated through functional and chemosensitivity assays on the human ABCB1-gene-transfected L5178Y mouse T-lymphoma cell line.</s><s>Structure−activity relationships showed that addition of electron-donating groups to the aromatic moiety improved the activity.</s><s>The effects on the ATPase activity of the strongest modulator (1.3) and the inactive jolkinol D (1) were also investigated and compared.</s><s>Moreover, in the chemosensitivity assay, most of the compounds interacted synergistically with doxorubicin.</s><s>Compounds 1.1−1.10 and 2.1−2.4 were further assessed for their collateral sensitivity effect against the human cancer cells: EPG85−257 (gastric) and EPP85−181 (pancreatic), and the matching drug-selected cells EPG85-257RDB, EPG85-257RNOV, EPP85-181RDB, and EPP85-181RNOV.</s><s>The most promising ones (1.8 and 1.10) along with compound 3, previously selected, were investigated as apoptosis inducers.</s><s>The compounds were able to induce apoptosis through caspase-3 activation, with significant differences being observed between the parental and resistant cells.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>T hroughout the world, cancer continues to be a leading cause of mortality. <ref type="bibr" target="#b0">1</ref></s><s>Despite the number of advances in this field, the development of resistance to anticancer drugs constitutes one of the main problems for a successful treatment.</s><s>In the course of chemotherapy, multidrug resistance (MDR) is likely to occur, and as a result, tumors fail to respond to a broad spectrum of structurally and mechanistically diverse anticancer agents. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b2">3</ref></s><s>−6 In normal cells, this efflux pump takes part in the natural detoxifying system, recognizing xenobiotics and extruding them from the cytosol.</s><s>However, in cancer cells, ABCB1 overexpression causes a reduction of the cytosolic concentration of the anticancer agent.</s><s>This will lead to a treatment failure resulting in cross-resistance to several cytotoxic drugs, such as cisplatin, colchicine, vinblastine, paclitaxel, doxorubicin, and protein kinase inhibitors. <ref type="bibr" target="#b5">6</ref></s><s>The improvement of chemotherapies targeted to overcome cancer MDR holds promise for a selective and efficient cancer treatment.</s><s>Promising strategies to accomplish that purpose depend on the research of molecules capable of lessening the ABCB1 drug efflux, and the discovery of compounds with collateral sensitivity activity. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8</ref></s><s>he collateral sensitivity effect was first observed in bacteria, but nowadays it is being used as a powerful asset to study cancer MDR. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b8">9</ref></s><s>In resistant cancer cells, each genomic, proteomic, or metabolomic alteration that conferred advantages during chemotherapeutic pressure might be at the same time a way to create vulnerabilities.</s><s>The collateral sensitivity effect approach takes advantage of these vulnerabilities, converting them into new therapeutic targets. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11</ref></s><s>Consequently, drugresistant phenotypes can be more sensitive to alternate agents than the original parental cell line. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b10">11</ref></s><s>As a result, highly selective compounds can be found and characterized.</s></p><p><s>Anticancer drug discovery programs are increasing their interest in natural products. <ref type="bibr" target="#b11">12</ref></s><s>Nature presents a vast chemical space that was selected through evolution to interact with a wide range of biological targets.</s><s>Therefore, it is not surprising why natural compounds and their derivatives have become effective anticancer drugs. <ref type="bibr" target="#b12">13</ref></s><s>Owing to the fast pace of development of drug resistance, a growing chemical space is needed.</s><s>In this regard, Euphorbia macrocyclic diterpenoids of the jatrophane-and lathyrane-type have shown significant MDR reversal activity, by ABCB1 modulation and/or by selective targeting of MDR cancer cells.</s><s>−19 Despite this progress, understanding their anti-MDR mode of action is still lacking.</s></p><p><s>In a previous report, we discussed a small library of jolkinol D derivatives in order to study the impact of structural modifications on ABCB1 efflux modulation.</s><s>It was concluded that the presence of an aromatic moiety improved the inhibition of this efflux pump at noncytotoxic doses. <ref type="bibr" target="#b20">20</ref></s><s>oreover, these derivatives were evaluated for their collateral sensitivity effects, of which jolkinoate L (3, Figure <ref type="figure" target="#fig_0">1</ref>) displayed an interesting MDR-selective antiproliferative activity. <ref type="bibr" target="#b21">21</ref></s><s>In the sequence of this anti-MDR development project, we optimized jolkinol D (1) and jolkinodiol (2) scaffolds by generating a new set of derivatives (1.1−1.10 and 2.1−2.4) in order to obtain a higher MDR reversal effect.</s><s>This was assessed through the combination of ABCB1 modulation and collateral sensitivity effects.</s><s>Thus, compounds 1.1−1.10 and 2.1−2.4 were tested for their ability to modulate the drug efflux activity of ABCB1 and to resensitize MDR cells to doxorubicin in drug combination studies, using ABCB1-transfected mouse Tlymphoma L5178Y cells.</s><s>The type of interaction with the ATPase function of ABCB1 was also investigated for the parent molecule (1) and the strongest modulator (1.3).</s><s>−23 The most promising derivatives (1.8, 1.10), and jolkinoate L (3), were investigated for their potential as apoptosis inducers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>■ RESULTS AND DISCUSSION</head><p><s>Chemistry.</s><s>The previous structure−activity relationship (SAR) analysis of jolkinol D (1) derivatives showed that ABCB1 efflux modulation was enhanced when an aromatic ester moiety was added to the lathyrane scaffold. <ref type="bibr" target="#b20">20</ref></s><s>However, the role of aromatic electronic effects as well as hindrance effects on ABCB1 efflux activity was still to be investigated.</s><s>As a result, a new set of derivatives (1.1−1.10 and 2.1−2.4) was generated.</s><s>Jolkinoates J−T (1.1−1.7) were obtained by reaction of jolkinol D (1), isolated from Euphorbia piscatoria Ait.</s><s>(Euphorbiacae), <ref type="bibr" target="#b20">20</ref> with the respective aroyl chlorides in the presence of CH 2 Cl 2 , TEA, and DMAP (Scheme 1).</s><s>In parallel, to study the role of the free hydroxy group at C-15, jolkinolates A−D (2.1−2.4) were prepared using jolkinodiol (2) <ref type="bibr" target="#b20">20</ref> as parent molecule (Scheme 1).</s><s>Moreover, an adamantane derivative (1.8) and two carbonate esters, one aliphatic (1.9) and one aromatic (1.10), were also synthesized (Scheme 2), using silver triflate <ref type="bibr" target="#b24">24</ref> as catalyst.</s><s>The structures of the derivatives were assigned by 1D and 2D NMR and HRMS data.</s><s>The 1 H and <ref type="bibr" target="#b12">13</ref> C NMR data of compounds 1.1−1.10 and 2.1−2.4 were compared with those of jolkinol D (1) and jolkinodiol (2), respectively.</s><s>As expected, the main differences were found for C-3 and H-3, which showed paramagnetic effects in carbon and proton chemical shifts (ΔδC ≅ 0.2−6.4 and ΔδH ≅ 1.1−1.9</s><s>ppm), due to the presence of the ester function.</s><s>The β-carbons of the acyl derivatives (C-2 and C-4) also showed the anticipated diamagnetic effects (ΔδC ≅ 0.8 and 0.6−1.4</s><s>ppm, respectively).</s></p><p><s>ABCB1-MDR Reversal Activity.</s><s>In order to compare with the previous results, the same experimental design <ref type="bibr" target="#b20">20</ref> was followed.</s><s>The antiproliferative activity of the compounds was assayed against the parental mouse T-lymphoma cells (L5178Y-PAR), and the ABCB1-transfected counterpart (L5178Y-MDR), using the MTT assay.</s><s>The derivatives 1.1−1.10 and 2.1−2.4 did not show a significant antiproliferative profile (IC 50 &gt; 19 μM) for both cell lines (Table <ref type="table">S1</ref>).</s></p><p><s>Modulation of ABCB1 efflux was tested using the standard rhodamine-123 functional assay.</s><s>Whether a compound modulates ABCB1 efflux or not is given by the fluorescence activity ratio (FAR).</s><s>This ratio represents the accumulation of rhodamine-123 between L5178Y-MDR and L5178Y-PAR cells.</s><s>Modulation of ABCB1 is considered to occur when FAR values are higher than one.</s><s>Strong modulation of this transporter occurs when this ratio is higher than 10. <ref type="bibr" target="#b25">25</ref> The derivatives 1.1− 1.10 and 2.1−2.4 were tested at 2 and 20 μM (nontoxic concentrations), and verapamil, a standard modulator, was used as positive control.</s><s>When tested at 20 μM, all the lathyrane derivatives (1.1−1.10;</s><s>2.1−2.4)</s><s>caused a strong impairment of ABCB1 efflux activity, with FAR values ranging from 9.9 to 41.5 (Table <ref type="table">1</ref>).</s><s>The strongest modulators of this library were depicted based on the 2 μM data (Table <ref type="table">1</ref>).</s><s>Thus, the most efficient modulators were the jolkinol D derivatives 1.2, 1.3, 1.5−1.8,</s><s>and 1.10 and the jolkinoldiol derivative 2.1 (FAR values from 10.8 to 33.3).</s><s>These results are interesting because the ABCB1 reversal activity of verapamil (22 μM) was 12.5.</s></p><p><s>Structure−Activity Relationships.</s><s>The K-means clustering algorithm was used to highlight some of the possible relations between ABCB1 modulatory activity and the calculated physicochemical features.</s><s>As a result, four groups sharing a high degree of similarity, in terms of physicochemical properties and activity at 2 μM, were generated (Figure <ref type="figure" target="#fig_3">2</ref>).</s><s>The first cluster grouped the derivatives with the bulkier</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Journal of Natural Products</head><p><s>Article substituents (1.4,</s><s>1.6, 1.7, 1.8, and 2.4), therefore showing the highest MW, MV, logP, MR, and ASA values (Figure <ref type="figure" target="#fig_3">2</ref>).</s><s>The strongest ABCB1 modulators 1.2, 1.3, and 1.5 were grouped mainly due to the FAR values, since their physicochemical properties are shared by compounds in clusters I and III (Figure <ref type="figure" target="#fig_3">2</ref>).</s><s>Cluster III comprised the jolkinodiol derivatives 2.1−2.3 as well as compounds 1.1 and 1.10.</s><s>Jolkinocarbonate A (1.9) occupied cluster IV.</s><s>Nevertheless, contrary to what was described for the first set of jolkinol D derivatives, <ref type="bibr" target="#b20">20</ref> no significant correlations were found between the computed physicochemical properties and ABCB1 modulatory activity.</s><s>This can be suggestive of a stronger role of the sum of other structural aspects, than the contribution of a single physicochemical property.</s><s>In fact, a recent in silico study, through 2D and 3D Q(quantitative)SAR, concluded that the conformation of the lathyrane macrocyclic scaffold and its substitution pattern (related to steric and electrostatic factors) were the main determinants for the ABCB1 modulation activity. <ref type="bibr" target="#b19">19</ref></s><s>herefore, to investigate the former observations, attention was focused on the SAR of esters containing the aromatic moiety; in this way, we compared the previous results <ref type="bibr" target="#b20">20</ref> with those described herein.</s><s>Thus, in comparison to jolkinoate I, <ref type="bibr" target="#b20">20</ref> bearing an unsubstituted aroyl moiety (FAR = 24.2), the introduction of trifluormethyl, an electron-withdrawing group, at the meta or para positions of the benzene moiety, lead to a  2), displaying an m-methyl group, was nearly inactive.</s><s>However, jolkinoate J, <ref type="bibr" target="#b20">20</ref> possessing this moderate electron-donating group at the para position, retained a strong modulatory character (FAR = 21.1).</s><s>The effects of a strong electron-donating group were investigated by using the methoxy group; nevertheless, differences in activity were not significant.</s><s>Incorporation of this group at the ortho (1.3; FAR = 33.3)</s><s>and para (jolkinoate K; FAR = 28.1) <ref type="bibr" target="#b20">20</ref></s><s>positions seemed to have a slightly higher electronic influence due to the resonance effects than its regioisomer at the meta position (1.2;</s><s>FAR = 26.1).</s><s>Moreover, jolkinoate R (1.5; FAR = 28.6),</s><s>bearing a cinnamoyl moiety, was also among the strongest modulators, suggesting that the aromatic conjugated system is a contributor toward ABCB1 modulation.</s></p><p><s>The potential steric hindrance on ABCB1 efflux modulation was studied by inclusion of bulky groups such as naphthoyl (1.6; FAR = 11.9),</s><s>biphenoyl (1.7; FAR = 11.6), and adamantoyl (1.8; FAR = 12.6).</s><s>The 2-fold reduction of modulatory efficiency, when compared to jolkinoate I (FAR = 24.2), <ref type="bibr" target="#b20">20</ref></s><s>suggests that introduction of a bicyclic moiety potentiates steric clashes within the drug-binding pocket of ABCB1, independently from its aromatic nature.</s><s>Similar observations were found by Jiao and co-workers, which verified that lathyrol derivatives with 1-naphthylacetyl or phenylacetyl substituents lost ABCB1 modulatory ability. <ref type="bibr" target="#b26">26</ref></s><s>urthermore, some derivatives of jolkinodiol (2) were included to test the role of a free hydroxy group at C-15.</s><s>Jolkinolate A (2.1), bearing a 3-methoxybenzoyl moiety at C-3, showed a 2-fold loss in efficacy in comparison to jolkinoate O (1.2), where the hydroxy group at C-15 is acetylated.</s><s>The same tendency was observed for the jolkinoldiol derivatives 2.2, 2.3, and 2.4 in comparison to their respective counterparts 1.4, 1.6,</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Journal of Natural Products</head><p><s>Article and 1.7 (Table <ref type="table">1</ref>).</s><s>Thus, the presence of the acetyl group at C-15 as a hydrophobic center or hydrogen-bond acceptor moiety might be more important for recognition/interaction with ABCB1 than the presence of a hydrogen-bond donor.</s><s>These findings are in accordance with the in-house pharmacophore model, based on macrocyclic diterpenoids and other ABCB1 inhibitors, in which the recognition pattern contains three hydrophobic moieties and one hydrogen-bond acceptor group. <ref type="bibr" target="#b13">14</ref></s><s>n conclusion, with this SAR study a favorable optimization for jolkinoates as ABCB1 modulators was achieved.</s><s>Benzoyl moieties with electron-donating groups should increase the electrostatic interactions and π-stacking at the drug-binding pocket of ABCB1, resulting in a more powerful ABCB1 efflux modulation.</s></p><p><s>Effects on the ATPase Activity of ABCB1.</s><s>ATP hydrolysis is linked with the ABCB1 efflux activity. <ref type="bibr" target="#b27">27,</ref><ref type="bibr" target="#b28">28</ref></s><s>The way how compounds affect this catalytic activity can give insights about their properties as substrate or inhibitor.</s><s>Therefore, the effects on the ATPase activity of this membrane transporter were evaluated for the parent compound jolkinol D (1) and the most active modulator of this set of lathyranes, jolkinoate P (1.3).</s><s>This activity was assessed through the production of inorganic phosphate directly resulting from the ATP hydrolysis of human ABCB1 expressed in purified insect membrane vesicles (Sf9).</s><s>Vanadate is a phosphate analogue that inhibits ABCB1 ATPase activity; therefore, the results obtained are presented as the vanadate sensitive ATPase activity.</s><s>This ATPase experiment is composed of two complementary assays.</s><s>The activation assay classifies compounds as stimulators or inhibitors of the baseline vanadate sensitive ATPase activity.</s><s>The inhibition assay, performed in the presence of a known ABCB1 activator, is used to characterize efflux inhibitors (or slowly transported substrates) through the decrease of verapamil-stimulated vanadate-sensitive ATPase activity.</s><s>Verapamil (40 μM) and cyclosporin A (40 μM) were used as positive controls in the activation and inhibition assays, respectively.</s><s>Jolkinol D (1) and jolkinoate P (1.3) were tested in a dose-dependent manner, and the effects were shown as the relative ATPase activity, in which the stimulated vanadate-sensitive ATPase activity is taken as 100% and the baseline vanadate-sensitive ATPase activity as 0%.</s></p><p><s>Jolkinol D (1) enhanced the basal ATPase activity with 66− 87%, though this stimulation was not dose dependent (Figure <ref type="figure" target="#fig_4">3A</ref>, activation assay).</s><s>These findings indicate that compound 1 interacts with the membrane transporter ABCB1.</s><s>Concerning the verapamil-stimulated ATPase activity, jolkinol D (1) showed an inhibitory effect of 14−40%, in the range 3.13− 12.5 μM (Figure <ref type="figure" target="#fig_4">3A</ref>, inhibition assay).</s><s>At higher concentrations (25−100 μM), compound (1) showed 9−33% stimulation of the verapamil-stimulated ATPase activity (Figure <ref type="figure" target="#fig_4">3A</ref>, inhibition assay).</s><s>The results from this ATPase assay suggest jolkinol D (1) to be a transported substrate of ABCB1, which at some concentrations can affect verapamil transport (inhibition or stimulation).</s><s>Nevertheless, it should be noted that jolkinol D (1) did not affect ABCB1 efflux at 2 or 20 μM. <ref type="bibr" target="#b20">20</ref></s><s>nteresting results were obtained with the strong modulator jolkinoate P (1.3).</s><s>The direct interaction with ABCB1 is shown through the activation of the ATPase activity (Figure <ref type="figure" target="#fig_4">3B</ref>, activation assay).</s><s>This activation occurred to a lower extent compared to jolkinol D (1).</s><s>Moreover, at higher doses (&gt;50 μM), jolkinoate P (1.3) inhibited ABCB1 ATPase activity.</s><s>This type of dose-dependent activation of ATPase activity at low concentrations and inhibition at higher concentrations was observed for several compounds. <ref type="bibr" target="#b29">29,</ref><ref type="bibr" target="#b30">30</ref></s><s>Recently, a conformationally gated model of drug-induced activation of ABCB1mediated ATP hydrolysis was established to study this issue. <ref type="bibr" target="#b30">30</ref></s><s>ccording to this model, when verapamil occupies the H-site of the ABCB1 drug-binding pocket, ATP hydrolysis and transport are maximized at low concentrations of verapamil.</s><s>When verapamil is present in high concentrations, it occupies both the H-site and a low affinity binding site; due to this, the protein is stabilized into an "intermediate" conformation that prevents ATP from driving ABCB1 to the ''closed" conformation.</s><s>Consequently, the verapamil transport and verapamil-stimulated ATP hydrolysis are reduced.</s><s>These findings might help to understand the jolkinoate P (1.3) dose effect on the ABCB1 ATPase activity.</s></p><p><s>When tested concomitantly with a second substrate, jolkinoate P (1.3) was able to diminish the verapamilstimulated ATPase activity, with a complete inhibition at 1.56 and 25 μM (Figure <ref type="figure" target="#fig_4">3B</ref>, inhibition assay).</s><s>This indicated that jolkinoate P (1.3) was capable of ceasing the transport of verapamil, through direct interaction with ABCB1.</s><s>Moreover, the inhibition assay also suggested jolkinoate P (1.3) to elicit a biphasic dose response on the ABCB1 ATPase.</s><s>This biphasic nature was observed for some compounds and might be attributed to the polyspecificity of ABCB1 drug-binding sites. <ref type="bibr" target="#b31">31</ref></s><s>erapamil and rhodamine-123 have different binding sites within the drug-binding pocket of ABCB1. <ref type="bibr" target="#b32">32,</ref><ref type="bibr" target="#b33">33</ref></s><s>Relating the results obtained in this work, it can be suggested that compound 1.3 might act as a modulator and/or a slowly</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Journal of Natural Products</head><p><s>Article transported substrate affecting the transport of these two molecules.</s></p><p><s>Chemosensitization: Reversion of Drug-Induced Resistance.</s><s>In order to test if the lathyrane derivatives would turn L5178Y-MDR cells more susceptible to anticancer drug action, their combinations with doxorubicin were tested.</s><s>The nature of the drug interactions was determined by the combination index (CI) as synergistic, additive, or antagonistic (Table <ref type="table" target="#tab_0">2</ref>). <ref type="bibr" target="#b34">34,</ref><ref type="bibr" target="#b35">35</ref></s><s>Apart from jolkinoates R (1.5) and U (1.8), and jolkinocarbonate A (1.9), that showed an antagonistic effect on the combination assay (CI = 1.11−2.02,</s><s>Table <ref type="table" target="#tab_0">2</ref>), the remaining derivatives improved the cytotoxicity of doxorubicin synergistically (CI = 0.20−0.84).</s><s>The modulators were able to restore sensitivity to doxorubicin by reversing the ABCB1-MDR phenotype.</s></p><p><s>Collectively the results from the transport (Table <ref type="table">1</ref>) and drug combination assays (Table <ref type="table" target="#tab_0">2</ref>) showed that the tested resistance modulators were able to affect ABCB1 efflux activity and to restore sensitivity to doxorubicin (except compounds 1.5, 1.8, and 1.9).</s><s>This is an interesting finding because the cytotoxic efficacy of doxorubicin is known to be affected by ABCB1 activity. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b36">36</ref></s><s>Moreover, it is interesting to note that, although jolkinoates R (1.5) and U (1.8) were strong ABCB1 modulators at 2 μM, they displayed antagonistic effects in the combination experiments.</s><s>These compounds might be targeting other cellular pathways and, thus, may antagonize the doxorubicin effect by competing or inhibiting its targets, independently from interaction with ABCB1.</s></p><p><s>Conversely, jolkinol D (1), a non-ABCB1 modulator, showed a synergistic effect with doxorubicin. <ref type="bibr" target="#b20">20</ref></s><s>Recalling the nature of interaction with ATPase, jolkinol D (1) was qualified as a transported substrate, and this result might contribute to explaining why the combination between this nonmodulator and the cytotoxic drug showed a synergistic nature. <ref type="bibr" target="#b20">20</ref></s><s>herefore, this compound might have more affinity or compete with doxorubicin for ABCB1 transport, suggesting accumulation of doxorubicin to the detriment of jolkinol D (1) efflux.</s></p><p><s>Collateral Sensitivity Effect.</s><s>In a preceding study, some jolkinol D derivatives were assessed for their potential selective antiproliferative activity against parental gastric (EPG85-257) and pancreatic (EPP85-181) human cancer cells and their drugresistant counterparts, selected against mitoxantrone (RNOV) or daunorubicin (RDB), respectively, using a proliferation assay. <ref type="bibr" target="#b21">21</ref></s><s>Most of those derivatives exhibited selective antiproliferative activity effects toward the EPG85-257RDB cell line.</s><s>However, jolkinoate L (3) showed a remarkable ability to target different cellular contexts with concomitant high antiproliferative activity. <ref type="bibr" target="#b21">21</ref></s><s>As a continuation of this development program, herein compounds 1.1−1.10 and 2.1−2.4 were investigated for their potential collateral sensitivity effect on the same cancer entities (Tables <ref type="table" target="#tab_1">S2 and S3</ref>, Supporting Information).</s></p><p><s>The MDR-selective activity was assessed by the relative resistance ratio (RR = IC 50(resistant) /IC 50(parental) ).</s><s>RR &lt; 1 indicates that the compound kills MDR cells more effectively than parental cells, but if RR &lt; 0.5, a collateral sensitivity effect is taking place. <ref type="bibr" target="#b9">10</ref></s><s>The cytotoxic agents etoposide and cisplatin were used as positive controls.</s><s>The antiproliferative activity and collateral sensitivity effects of compounds 1.1−1.10 and 2.1− 2.4 are shown as a heat map table <ref type="table" target="#tab_1">(Table 3</ref>).</s><s>This representation enables the identification of compounds that show MDR-selective activity at a determined IC 50 level.</s><s>Most of the derivatives were highly effective toward the resistant gastric cell lines, exhibiting an antiproliferative activity comparable to the positive controls cisplatin and etoposide (Table <ref type="table" target="#tab_1">3</ref>, Table <ref type="table" target="#tab_0">S2</ref>, Supporting Information).</s><s>The collateral sensitivity effect (RR ≤ 0.5) was mostly observed for EPG85-257RDB cells, which are characterized by ABCB1 overexpression. <ref type="bibr" target="#b37">37</ref></s><s>With respect to EPG85-257RNOV cells, the best results were obtained for</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Journal of Natural Products</head><p><s>Article compounds 1.1, 1.4, 1.8, 1.9, 1.10, and 2.3, which showed IC 50 values lower than 10 μM (Table <ref type="table" target="#tab_1">3</ref>, Table <ref type="table" target="#tab_0">S2</ref>), but only derivatives 1.4 and 2.3 showed a collateral sensitivity effect (RR &lt; 0.5).</s><s>Nevertheless, no structure−activity relationships could be inferred for these cell lines.</s><s>Based on the IC 50 and RR values (Table <ref type="table" target="#tab_1">3</ref>, Table <ref type="table" target="#tab_0">S2</ref>), jolkinocarbonate B (1.10) (6.24 ± 1.08 μM, 5.55 ± 0.88 μM, and 2.34 ± 0.67 μM, against EPG85-257P, EPG85-257RNOV, and EPG85-257RDB, respectively) was selected for apoptosis induction studies.</s></p><p><s>Regarding the pancreatic cancer cell lines, the tested compounds were less active (Table <ref type="table" target="#tab_1">3</ref>, Table <ref type="table" target="#tab_1">S3</ref>, Supporting Information).</s><s>Thus, based on IC 50 values, only jolkinoate U (1.8) (8.61 ± 0.58 μM against EPP85-181P; 6.63 ± 0.95 μM against EPP85-181RNOV; and 5.86 ± 0.07 μM against EPP85-181RDB) was chosen for further studies.</s></p><p><s>Annexin V/PI Assay and Active Caspase-3 Assay.</s><s>Jolkinoate L (3) showed a remarkable ability to target both gastric and pancreatic MDR contexts. <ref type="bibr" target="#b21">21</ref></s><s>Likewise, jolkinocarbonate B (1.10) showed interesting results against gastric cells and jolkinoate U (1.8) against pancreatic cells (Table <ref type="table" target="#tab_1">3</ref>, Tables <ref type="table" target="#tab_0">S1 and S2</ref>, Supporting Information).</s><s>Hence, their ability as apoptosis inducers was evaluated.</s><s>The annexin V/propidium iodide (PI) assay was used to assess if compounds 3, 1.8, and 1.10 (30 μM) would induce apoptosis.</s><s>Caspase activation was measured with the active caspase-3 assays.</s><s>Detection of these events was performed by flow cytometry after 72 h exposure.</s><s>The results of total apoptosis (early and late apoptotic events) and caspase-3 activation were expressed as fold increase (ratio between treated samples and untreated samples).</s></p><p><s>Jolkinoate L (3), a trifluormethylbenzoyl derivative, induced apoptosis in the gastric cell lines about 4-fold in EPG85-257P and EPG85-257RNOV, and created a statistically significant 6fold induction in EPG85-257RDB (Figure <ref type="figure" target="#fig_7">4A</ref>).</s><s>Through the caspase-3 data (Figure <ref type="figure" target="#fig_7">4A</ref>), it could be concluded that the druginduced cytotoxicity occurred via caspase-mediated apoptosis, since there was a caspase-3 activation of 6−9-fold.</s><s>On the other hand, jolkinoate L (3) induced significant selective apoptosis in the pancreatic MDR phenotypes EPP85-181RNOV and EPP85-181RDB, in about 4.5-and 3.5-fold, respectively (Figure <ref type="figure" target="#fig_7">4B</ref>).</s><s>In the same way as in the gastric cell lines, the apoptotic process occurred through caspase-3 activation.</s><s>Remarkable results were found for EPP85-181RNOV, showing a 12-fold activation of this apoptosis effector protein (Figure <ref type="figure" target="#fig_7">4B</ref>).</s></p><p><s>Moreover, jolkinocarbonate B (1.10) showed a statistically significant apoptosis induction in the gastric EPG85-257RNOV cells, but with little apoptosis induction in EPG85-257P or EPG85-257RDB (Figure <ref type="figure" target="#fig_7">4C</ref>).</s><s>This selective targeting of EPG85-257RNOV cells was corroborated by the caspase-3 activation data (Figure <ref type="figure" target="#fig_7">4C</ref>).</s><s>Although little apoptosis induction was detected for EPG85-257P and EPG85-257RDB cells, caspase-3 activation was taking place (Figure <ref type="figure" target="#fig_7">4C</ref>).</s><s>Therefore, a quantifiable apoptosis induction may occur after 72 h.</s></p><p><s>The adamantoyl derivative jolkinoate U (1.8) showed statistically significant selective apoptosis induction between the resistant pancreatic cells (EPP85-181RNOV; EPP85-181RDB) and the parental cells; with a 5-fold apoptosis induction on EPP85-181RNOV and a 17-fold induction on EPP85-181RDB.</s><s>The observed apoptotic processes were Rhodamine 123 Accumulation Assay.</s><s>The mouse T-lymphoma cells L5178Y (ECACC catalogue no.</s><s>87111908, U.S. FDA, Silver Spring, MD, USA) and the ABCB1-transfected L5178Y mouse Tlymphoma cells were established and cultured as described. <ref type="bibr" target="#b20">20,</ref><ref type="bibr" target="#b38">38</ref></s><s>The cells were resuspended in serum-free McCoy's 5A medium in 500 μL aliquots adjusted of 2 × 10 6 /mL.</s><s>The lathyrane derivatives were added at 2 and 20 μM, the positive control verapamil (EGIS Pharmaceuticals PLC, Budapest, Hungary) at 20 μM, and the solvent control DMSO at 2% (v/v).</s><s>The incubation of the samples took place at room temperature for 10 min, after which 10 μL (5.2 μM) of rhodamine-123 was added.</s><s>The samples were washed twice after incubation at 37 °C for 20 min, resuspended in phosphate-buffered saline (500 μL), and analyzed by flow cytometry (Partec CyFlow Space instrument, Partec GmbH, Munster, Germany).</s><s>The histograms were assessed concerning the mean fluorescence intensity (FL-1), standard deviation, and peak channel of 20,000 individual cells belonging to the total and gated populations.</s><s>The fluorescence activity ratio (FAR) was calculated as FAR = (L5178Y-MDR F L -1 t r e a t e d /L5178Y-MDR F L -1 c o n t r o l )/ (PAR FL-1treated /PAR FL-1control ).</s></p><p><s>ATPase Assay.</s><s>The SB-MDR1 PREADEASY ATPase Kit (SOLVO Biotechnology, Szeged, Hungary) was preformed according to the manufacturer's instructions.</s><s>The purified Sf9 insect membrane vesicles (4 μg protein/well), expressing high levels of human MDR1, were incubated in 50 μL of ATPase assay buffer, compound, and 2 mM MgATP, for 10 min at 37 °C.</s><s>The final concentration of DMSO in the experiment was 2% (v/v).</s><s>The ATPase reaction was stopped, and the inorganic phosphate (Pi) production was measured colorimetrically (optical density was read at 630 nm).</s><s>The amount of Pi produced is proportional to the ABCB1 activity.</s><s>Hence, ATPase activities were determined as the difference of the measured Pi liberation with and without the presence of 1.2 mM sodium orthovanadate (vanadate-sensitive ATPase activity).</s><s>This ATPase kit comprises two different tests: the activation and inhibition assays.</s><s>When the test compound can stimulate the baseline vanadate-sensitive ATPase activity (activation assay), it reflects the ABCB1 transported, as is the case of verapamil (40 μM), used as positive control.</s><s>The inhibition assay assesses the effect of a second transported substrate on ABCB1 ATPase activity.</s><s>Thus, the compounds are tested in the presence of verapamil (40 μM).</s><s>Inhibitors of ABCB1 may reduce the verapamil-stimulated vanadate-sensitive ATPase activity.</s><s>In some cases, inhibitors may inhibit the baseline transporter ATPase activity as well, such as cyclosporine A (40 μM), also used as positive control.</s></p><p><s>Antiproliferative Assay and Drug Combination Studies.</s><s>The antiproliferative assay was performed according to a published procedure. <ref type="bibr" target="#b20">20</ref></s><s>The parental (PAR) and multidrug-resistant (MDR) ABCB1-transfected L5178Y mouse T-lymphoma cells were seeded at 1 × 10 5 /mL and incubated with a concentration gradient of compounds (final volume of 200 μL/well) for 72 h (5% CO 2 at 37 °C).</s><s>The final concentration of DMSO in the experiment was 1% (v/v).</s><s>Cell growth was determined by measuring the optical density (OD) at 550 nm (ref 630 nm) with a Multiscan EX ELISA reader (Thermo Labsystems, Cheshire, WA, USA); and determined as 100 − [(OD sample − OD mediumcontrol )/(OD cellcontrol − OD mediumcontrol )] × 100.</s><s>Mean IC 50 values were obtained from three independent experiments for each cell line, by best fitting the dose-dependent inhibition curves in the GraphPadPrism5 program.</s></p><p><s>Drug combinations of doxorubicin (Teva) and the compounds were designed and evaluated according to Chou using the software CalcuSyn Version 2. <ref type="bibr" target="#b34">34,</ref><ref type="bibr" target="#b35">35</ref> Since the optimal concentration range for the combination is not known, the most appropriated experimental design is by using several concentrations of each agent, with data points above and below IC 50 .</s><s>The experimental design followed the checkerboard microplate method, where dilutions of doxorubicin were made in a horizontal direction and the dilutions of resistance modifiers vertically in a microtiter plate to a final volume of 200 μL of medium per well.</s><s>The L5178Y-MDR cells were distributed at 2 × 10 5 cells/mL per well and were incubated for 48 h under standard conditions.</s><s>The cell growth rate was determined after MTT staining, as previously described. <ref type="bibr" target="#b20">20</ref></s><s>Each drug combination produces an effect, and constant ratios ([compound]/[doxorubicin]) can be taken from the diagonals of the checkerboard.</s><s>The effect of each constant ratio across a concentration gradient was computed in CalcuSyn software.</s><s>More details concerning the CalcuSyn model and combination index calculation can be assessed in the Supporting Information.</s></p><p><s>Collateral Sensitivity Assays: Antiproliferative Assay.</s><s>Cell culture procedures of the human carcinoma cell lines (EPG85-257P and EPP85-181P) and their drug-resistant sublines (EPG85-257RNOV, EPG85-257RDB, EPP85-181RNOV, EPP85-181RDB) have been described previously. <ref type="bibr" target="#b21">21</ref></s><s>Briefly, 5 × 10 3 /mL (EPG85-257P and EPP85-181P) and 7.5 × 10 3 /mL (EPG85-257RNOV, EPG85-257RDB, EPP85-181RNOV, EPP85-181RDB) were seeded.</s><s>After attachment (48 h), the compounds were added in a dilution series for incubation during 5 days (5% CO 2 at 37 °C).</s><s>The final concentration of DMSO in the experiment was 0.3% (v/v).</s><s>Cell growth was based on sulforhodamine B (SRB) staining and was performed according to a published procedure. <ref type="bibr" target="#b21">21</ref></s><s>Cell growth was measured at 562 nm against the reference wavelength of 690 nm.</s><s>Mean IC 50 values were obtained from three to four independent experiments in triplicate for each cell line, by best fitting the dose-dependent inhibition curves in the GraphPadPrism5 program.</s><s>Relative resistance (RR) values were calculated as IC 50(resistant cells) /IC 50(parental cells) .</s></p><p><s>Annexin V/PI Staining and Active Caspase-3 Assay.</s><s>An FITC Annexin V apoptosis detection kit (BD Pharmingen, BD Biosciences) was used to detect cytotoxic drug-induced apoptosis.</s><s>The intracellular presence of active caspase-3 was detected using an FITC Active Caspase-3 Apoptosis Kit (BD Pharmingen, BD Biosciences).</s><s>Both assays followed the same experimental design.</s><s>Briefly, 6 × 10 4 cell/mL of parental cell lines (EPG85-256P and EPP85-181P) and 1 × 10 5 cell/mL of resistant cell lines (EPG85-256RNOV, EPG85−256RDB, EPP85-181RNOV, and EPP85-181RDB) were seeded in six-well plates in complete medium and attached for 24 h.</s><s>The medium was thrown away the next day, and new medium (with 30 μM of compounds) was added to the cancer cells.</s><s>The final concentration of DMSO in the experiment was 0.3% (v/v).</s><s>Camptothecin (Cayman Chemicals, Ann Arbor, Michigan, USA) was used as positive control (1 μM).</s><s>Cells were further incubated for 72 h (5% CO 2, 37 °C).</s><s>The concentration of compounds and positive control, and incubation time were optimized in order to ensure a good sampling for flow cytometry measurement of the apoptotic process (data not shown).</s><s>After this incubation period, cells were trypsinized, washed in PBS, and stained according to each kit manufacturer's instructions.</s><s>Stained cells were analyzed using a BD Accuri C6 flow cytometer (BD Pharmingen, BD Biosciences), and data were processed with BD Accuri C6 software.</s><s>Each sample was assessed using a collection of 10 000 events.</s><s>The mean values and standard deviations were calculated from three independent experiments.</s></p><p><s>Statistical Analysis.</s><s>K-means clustering, which subdivides the compounds (those with the nearest mean) into groups that exhibit a high degree of similarity, was performed with Tanagra, version 1.4.41</s><s>(https://eric.univ-lyon2.fr/~ricco/tanagra/). Statistical evaluation of the apoptosis assays data was performed with the two-tailed unpaired Student's t test using GraphPadPrism5 software.</s><s>Probability value p &lt; 0.05 was considered statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Journal of Natural Products</head><p><s>Article</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Jolkinoate L (3).</s></p></div></figDesc><graphic coords="2,130.00,399.69,100.91,85.89" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Scheme 1 .</head><label>1</label><figDesc><div><p><s>Scheme 1. Preparation of Jolkinoates N−T (1.1−1.7) and Jolkinolates A−D (2.1−2.4) a</s></p></div></figDesc><graphic coords="3,129.88,85.21,365.16,492.32" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Modulation of ABCB1-Mediated Rhodamine-123 Efflux by Jolkinol D Derivatives 1.1−1-10 and Jolkinodiol Derivatives 2.1−2.4 a FAR = (L5178Y-MDR FL-1treated /L5178Y-MDR FL-1control )/(L5178Y-PAR FL-1treated /L5178Y-PAR FL-1control ).</s><s>FL-1: mean fluorescence intensity of the cells.</s><s>Verapamil (22 μM) FAR = 12.5.</s><s>DMSO (2%) FAR = 0.87.</s><s>Journal of Natural Products Article decreased efflux modulatory efficiency [(2.5-fold)</s><s>FAR = 9.3 and 9.4, respectively to jolkinoate L 20 and 1.4].</s><s>Likewise, jolkinocarbonate B (1.10; FAR = 10.8) with a phenyl substituent, lost modulatory ability in comparison to jolkinoate I. Jolkinoate N (1.1;</s><s>FAR = 2.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Cluster analysis of compounds 1.1−1.10 and 2.1−2.4.</s><s>Box and whiskers plot representing each grouping variable: FAR values (2 μM), molecular weight (MW), molecular volume (MV), logP prediction developed at Molinspiration (logP), molar refractivity (MR), topological polar surface area (TPSA), and accessible solvent area (ASA).</s><s>Physicochemical properties were calculated using JME molecular editor, version July 2016, http://www.molinspiration.com/jme.</s></p></div></figDesc><graphic coords="5,162.48,69.17,299.96,435.35" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Effects of (A) jolkinol D (1) and (B) jolkinoate P (1.3) on ABCB1 ATPase activity.</s><s>Activation assay: tests the effect on the basal ATPase activity.</s><s>Inhibition assay: tests the effect on drug-stimulated ATPase activity, measured in the presence of verapamil (40 μM).</s><s>Results are expressed as the mean ± SD.</s><s>The effects of compounds are shown as the relative ATPase activity, in which the verapamilstimulated vanadate-sensitive ATPase activity is taken as 100% and the baseline vanadate-sensitive ATPase activity as 0%.</s></p></div></figDesc><graphic coords="6,346.05,69.17,196.78,272.01" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>a</head><label></label><figDesc><div><p><s>Data are shown as the best combination ratio of the tested compounds and doxorubicin.</s><s>b Combination index (CI) values are mean ± standard deviation (SD) for an inhibitory concentration of 50% (IC 50 ).</s><s>CI &lt; 0.1: very strong synergism; 0.1 &lt; CI &lt; 0.3: strong synergism; 0.3 &lt; CI &lt; 0.7: synergism; 0.7 &lt; CI &lt; 0.9: moderate to slight synergism; 0.9 &lt; CI &lt; 1.1: nearly additive; 1.10 &lt; CI &lt; 1.45: moderate antagonism; 1.45 &lt; CI &lt; 3.30: antagonism. 34,35</s><s>Compounds 1.1, 1.4, 2.2, and 2.4 are not assayed due to IC 50 &gt; 80 μM.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head></head><label></label><figDesc><div><p><s>(EPG85-257P, EPG85-257RNOV, and EPG85-257RDB) and Pancreatic Carcinoma Cells (EPP85-181P, EPP85-181RNOV, and EPP85-181RDB) a a This representation permits identifying compounds that show MDRselective activity at a determined IC 50 sevel.</s><s>Collateral sensitivity values (RR &lt; 0.5) are shown.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Induction of apoptosis and activation of caspase-3: (A) jolkinoate L (3) in gastric cells; (B) jolkinoate L (3) in pancreatic cells; (C) jolkinocarbonate B (1.10) in gastric cells; and (D) jolkinoate U (1.8) in pancreatic cancer cell lines.</s><s>Total apoptosis was considered the sum of early and late apoptotic events (cells annexin V positive/PI negative plus cells annexin V positive/PI positive).</s><s>The results were expressed as the ratio between treated and untreated samples.</s><s>Each column represents the mean ± SD (n = 3).</s><s>Statistical significance was calculated for the difference between treated resistant cell lines and treated parental cells using a two-tailed unpaired Student's t test.</s><s>*, p &lt; 0.05.</s><s>**, p &lt; 0.01.</s><s>***, p &lt; 0.001.</s></p></div></figDesc><graphic coords="8,162.48,69.17,299.96,284.83" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Drug Combination Experiments in ABCB1-Transfected Mouse T-Lymphoma Cells (L5178Y-MDR)</s></p></div></figDesc><table><row><cell>Combination with Doxorubicin</cell><cell>Ratio a</cell><cell>CI ± SD b</cell><cell>Interaction</cell></row><row><cell>Jolkinoate O (1.2)</cell><cell>25:1</cell><cell cols="2">0.84 ± 0.14 moderate synergism</cell></row><row><cell>Jolkinoate P (1.3)</cell><cell>10:1</cell><cell cols="2">0.09 ± 0.03 very strong</cell></row><row><cell></cell><cell></cell><cell></cell><cell>synergism</cell></row><row><cell>Jolkinoate R (1.5)</cell><cell>50:1</cell><cell cols="2">1.13 ± 0.37 slight antagonism</cell></row><row><cell>Jolkinoate S (1.6)</cell><cell>400:1</cell><cell cols="2">0.06 ± 0.02 very strong</cell></row><row><cell></cell><cell></cell><cell></cell><cell>synergism</cell></row><row><cell>Jolkinoate T (1.7)</cell><cell>100:1</cell><cell cols="2">0.32 ± 0.08 synergism</cell></row><row><cell>Jolkinoate U (1.8)</cell><cell>15:1</cell><cell cols="2">1.11 ± 0.37 slight antagonism</cell></row><row><cell>Jolkinocarbonate A (1.9)</cell><cell>5:1</cell><cell cols="2">1.22 ± 0.28 moderate</cell></row><row><cell></cell><cell></cell><cell></cell><cell>antagonism</cell></row><row><cell>Jolkinocarbonate B (1.10)</cell><cell>18:1</cell><cell cols="2">0.50 ± 0.07 synergism</cell></row><row><cell>Jolkinolate A (2.1)</cell><cell>50:1</cell><cell cols="2">0.38 ± 0.16 synergism</cell></row><row><cell>Jolkinolate C (2.</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Heat Map Table Summarizing the Antiproliferative and Collateral Sensitivity Results against Gastric Carcinoma Cells</s></p></div></figDesc><table /></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The authors declare no competing financial interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>■ ACKNOWLEDGMENTS</head><p><s>This study was financially supported by Fundacaõ para a Ciencia e a Tecnologia (FCT), Portugal (project PTDC/QEQ-MED/0905/2012; PhD grant SFRH/BD/72915/2010), German Egyptian Research Long-term Scholarship (GERLS) Program 2014 (57076387) provided by the German Academic Exchange Service (DAAD), and the contribution of the Foundation for Cancer Research Szeged, Hungary.</s><s>We also acknowledge Carlos Cordeiro, Faculdade de Ciencias, Universidade de Lisboa, for HRMS data (FCT, REDE/1501/ REM/2005).</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Soerjomataram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dikshit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rebelo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Parkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Forman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="E359" to="E386" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Lage</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell. Mol. Life Sci</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="3145" to="3167" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Gottesman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Lavi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-P</forename><surname>Gillet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu. Rev. Pharmacol. Toxicol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="85" to="102" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Holohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Schaeybroeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Longley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Johnston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="714" to="726" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Kartal-Yandim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Adan-Gokbulut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Baran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit. Rev. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">8551</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Gottesman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fojo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Bates</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="48" to="58" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Callaghan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Luk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bebawy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J C</forename><surname>Cuperus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Claudel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gautherot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Halilbasic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Trauner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Metab. Dispos</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="623" to="631" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Szakaćs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Gottesman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Boumendjel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kachadourian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Baubichon-Cortay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Di Pietro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chem. Rev</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="5753" to="5774" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">W</forename><surname>Szybalski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Bryson</surname></persName>
		</author>
		<author>
			<persName><surname>Bacteriol</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1952">1952</date>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="489" to="499" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Handley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Gottesman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Pharmacol. Sci</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="546" to="556" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Pluchino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Goldsborough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Callaghan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Gottesman</surname></persName>
		</author>
		<author>
			<persName><surname>Drug</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="98" to="105" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Edrada-Ebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Quinn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Drug Discovery</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="111" to="129" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Newman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Cragg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Nat. Prod</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page">461</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J V</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J U</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Guedes</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J. Chem. Inf. Model</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1315" to="1324" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Reis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Serly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Duarte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Madureira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J V</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Molnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ferreira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. U. Anti-Cancer Agents Med. Chem</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1015" to="1024" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Sousa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J U</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Molnaŕ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">X</forename><surname>Fernandes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Pharm. Sci</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="542" to="553" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Vieira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Duarte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Reis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Spengler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Madureira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Molnaŕ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J U</forename><surname>Ferreira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioorg. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="6392" to="6400" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Matos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Duarte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Spengler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Molnaŕ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J U</forename><surname>Ferreira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Nat. Prod</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="2215" to="2228" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Baptista</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">X</forename><surname>Fernandes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ferreira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Future Med. Chem</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="629" to="645" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Reis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J V</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Molnaŕ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J U</forename><surname>Ferreira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="748" to="760" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Reis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Paterna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J U</forename><surname>Ferreira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioorg. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="3696" to="3702" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Lage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Duarte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Coburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hilgeroth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ferreira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Phytomedicine</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="441" to="448" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Hilgeroth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baumert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Coburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Seifert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Krawczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hempel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Neubauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Molnaŕ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lage</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med. Chem</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="487" to="493" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chakraborty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Synthesis</title>
		<imprint>
			<date type="published" when="1621">2011, 2011, 1621−1625</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Voigt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Coburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Monaŕ</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hilgeroth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioorg. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="5110" to="5113" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">W</forename><surname>Jiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="3720" to="3738" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Chufan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Ambudkar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">In Adv. Cancer Res</title>
		<imprint>
			<biblScope unit="page" from="71" to="96" />
			<date type="published" when="2015">2015</date>
			<publisher>Elsevier Inc</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Ambudkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hrycyna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ramachandra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Pastan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Gottesman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu. Rev. Pharmacol. Toxicol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="361" to="398" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Dongping</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Promega Notes</title>
		<imprint>
			<biblScope unit="page" from="11" to="14" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Ledwitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Gibbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Barnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Roberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="96" to="108" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Calabrese</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit. Rev. Toxicol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="473" to="487" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Chufan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H.-M</forename><surname>Sim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Ambudkar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="71" to="96" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Zinzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Capparelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cantore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Contino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Leopoldo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Colabufo</surname></persName>
		</author>
		<author>
			<persName><surname>Front</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">T.-C</forename><surname>Chou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="440" to="446" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">T.-C</forename><surname>Chou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Rev</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="621" to="681" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Szakaćs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ludwig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Booth-Genthe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Gottesman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Drug Discovery</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="219" to="234" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Dietel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Niendorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="6100" to="6106" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">I</forename><surname>Pastan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Gottesman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ueda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lovelace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rutherford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Willingham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl. Acad. Sci. U. S. A</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="4486" to="4490" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
